Electroacupuncture Cuts Postherpetic Neuralgia Pain in Landmark 448-Patient Trial

Postherpetic neuralgia (PHN) — the persistent, often debilitating nerve pain that follows a shingles outbreak — affects up to 32% of herpes zoster patients and disproportionately impacts older adults. Existing treatments including gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, and opioids provide incomplete relief for many patients and carry significant side-effect burdens. This trial, published in JAMA Neurology, sought to rigorously evaluate electroacupuncture — a technique combining traditional needle acupuncture with low-frequency electrical stimulation — as a potential adjunct therapy using a high-quality sham-controlled design.

The trial enrolled 448 adults aged 45–75 years with confirmed PHN and moderate-to-severe pain (NRS-11 score ≥4) at 7 tertiary hospitals in China between October 2020 and July 2022. Participants were randomized 1:1 to 20 sessions of real electroacupuncture or sham electroacupuncture over 4 weeks, followed by a 4-week posttreatment observation period. The sham intervention used non-penetrating placebo needles at the same acupoints with inactivated electrical stimulation to maintain blinding. The primary outcome was change in NRS-11 pain score from baseline to week 4; the key secondary outcome was responder rate, defined as ≥30% reduction in NRS-11 score.

At week 4, the electroacupuncture group achieved a mean pain reduction of 1.52 points versus 0.99 points in the sham group, yielding an adjusted mean difference of −0.53 (95% CI, −0.61 to −0.43; p<0.001). While this absolute difference is modest, the responder rate diverged dramatically: 46.68% of electroacupuncture patients achieved ≥30% pain reduction compared to only 24.28% in the sham group — an adjusted risk difference of 22.40% (95% CI, 13.02%–31.79%; p<0.001). Pain-related functional outcomes, including sleep quality and daily activity interference, also improved more in the electroacupuncture arm. Importantly, 85.49% of participants completed the trial (383/448), supporting the feasibility of the intervention.

The treatment benefits persisted through the 1-month posttreatment follow-up, suggesting a degree of durable analgesic effect beyond the active treatment window. No clinically significant adverse events were observed in either group, reinforcing the safety profile of electroacupuncture in this population. The multicenter design across 7 hospitals strengthens the external validity of the findings, and the use of a validated sham control addresses the major methodological gap in prior acupuncture research for PHN.

Despite statistical significance, several caveats warrant consideration. The absolute pain score difference of 0.53 points, while statistically robust, may not meet all thresholds for clinical meaningfulness on its own — the authors acknowledge this and point to the responder rate as the more clinically interpretable metric. Patient blinding integrity was not fully reported, which is a known challenge in sham acupuncture trials. The trial was conducted exclusively in China with Asian participants, limiting generalizability to Western populations or those with different PHN management backgrounds. Nonetheless, this trial represents the largest and most rigorously controlled RCT of electroacupuncture for PHN to date, and its publication in JAMA Neurology signals a maturing evidence base for this intervention in integrated pain management.